Forte Biosciences (FBRX) Total Non-Current Liabilities (2016 - 2026)
Forte Biosciences (FBRX) reported Total Non-Current Liabilities of $23.6 million for Q1 2026, up 13.96% quarter-over-quarter from $20.8 million in Q4 2025.
Forte Biosciences (FBRX) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 5 years of Total Non-Current Liabilities data on file, last reported at $23.6 million in Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $23.6 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $23.6 million (changed N/A YoY), and the FY2025 annual result was $20.8 million, changed N/A from the prior year.
- Total Non-Current Liabilities climbed to $23.6 million in Q1 2026 per FBRX's latest filing, from $20.8 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $23.6 million in Q1 2026 and troughed at $20.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Forte Biosciences | 70.77 Mn | 12.55 Mn | - | 23.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.65 Mn |
| Dec 31, 2025 | 20.75 Mn |
| Dec 31, 2019 | 17.23 Mn |
| Sep 30, 2019 | 50.87 Mn |
| Mar 31, 2017 | 35.74 Mn |
| Dec 31, 2016 | 28.23 Mn |